• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.

作者信息

Hultcrantz Malin, Hassoun Hani, Korde Neha, MacLachlan Kylee, Mailankody Sham, Patel Dhwani, Shah Urvi A, Tan Carlyn Rose, Chung David J, Lahoud Oscar B, Landau Heather J, Scordo Michael, Shah Gunjan L, Giralt Sergio A, Pianko Matthew J, Burge Miranda, Barnett Kelly, Salcedo Meghan, Caple Julia, Tran Linh, Blaslov Jenna, Shekarkhand Tala, Hamid Selena, Nemirovsky David, Derkach Andriy, Arisa Oluwatobi, Peer Cody J, Figg William D, Usmani Saad Z, Landgren Ola, Lesokhin Alexander M

机构信息

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1.

DOI:10.1038/s41408-024-01136-1
PMID:39300066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11412964/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c8d/11412964/f1391caa2d47/41408_2024_1136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c8d/11412964/4729a9e3297d/41408_2024_1136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c8d/11412964/f1391caa2d47/41408_2024_1136_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c8d/11412964/4729a9e3297d/41408_2024_1136_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c8d/11412964/f1391caa2d47/41408_2024_1136_Fig2_HTML.jpg

相似文献

1
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.考来维仑用于治疗多发性骨髓瘤患者中与来那度胺相关的腹泻。
Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1.
2
Two cases of reversible Fanconi syndrome induced by lenalidomide.
Leuk Lymphoma. 2019 Apr;60(4):1092-1094. doi: 10.1080/10428194.2018.1515941. Epub 2018 Oct 2.
3
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.考来维仑用于治疗多发性骨髓瘤患者中与来那度胺相关的腹泻。
Res Sq. 2024 Jun 5:rs.3.rs-4406606. doi: 10.21203/rs.3.rs-4406606/v1.
4
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.来那度胺诱发的骨髓瘤患者腹泻是由胆汁酸吸收不良引起的，这种情况对治疗有反应。
Blood. 2014 Oct 9;124(15):2467-8. doi: 10.1182/blood-2014-06-583302.
5
Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease.来那度胺在亚临床克雅氏病中诱发可逆性帕金森症、肌张力障碍和痴呆。
J Neurol Sci. 2018 Oct 15;393:140-141. doi: 10.1016/j.jns.2018.08.027. Epub 2018 Aug 28.
6
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.英地昔单抗瑞妥昔单抗联合来那度胺或泊马度胺治疗复发/难治性多发性骨髓瘤的多中心 1/2a 期研究。
Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13.
7
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.帕比司他、来那度胺、硼替佐米联合地塞米松治疗复发和复发/难治性多发性骨髓瘤的 1 期开放性研究。
Blood Cancer J. 2021 Feb 5;11(2):20. doi: 10.1038/s41408-021-00407-5.
8
A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report.一名在来那度胺治疗期间发生缺血性结肠炎的多发性骨髓瘤患者：一例罕见病例报告。
J Oncol Pharm Pract. 2020 Sep;26(6):1499-1500. doi: 10.1177/1078155219900910. Epub 2020 Feb 6.
9
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.硼替佐米、来那度胺和地塞米松联合帕比司他用于适合移植的多发性骨髓瘤患者的一线治疗：一项1期试验。
Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.
10
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.接受自体干细胞移植后来那度胺维持治疗的多发性骨髓瘤患者中克隆性造血的临床相关性及预后影响
Am J Hematol. 2021 May 1;96(5):E157-E162. doi: 10.1002/ajh.26125. Epub 2021 Feb 23.

本文引用的文献

1
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.三药联合治疗、移植和维持治疗直至骨髓瘤进展。
N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5.
2
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.美国国立综合癌症网络（NCCN）指南见解：多发性骨髓瘤，2022年第3版
J Natl Compr Canc Netw. 2022 Jan;20(1):8-19. doi: 10.6004/jnccn.2022.0002.
3
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.硼替佐米联合地塞米松治疗多发性骨髓瘤患者的临床疗效及不良反应观察
Br J Clin Pharmacol. 2019 May;85(5):924-934. doi: 10.1111/bcp.13873. Epub 2019 Feb 27.
4
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.多发性骨髓瘤患者的维持治疗与生存：系统评价和网络荟萃分析。
JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.
5
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.来那度胺维持治疗在新诊断的多发性骨髓瘤自体干细胞移植后的应用：一项荟萃分析。
J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.
6
Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.健康志愿者和血液恶性肿瘤患者来那度胺的群体药代动力学。
Clin Pharmacol Drug Dev. 2018 Jun;7(5):465-473. doi: 10.1002/cpdd.372. Epub 2017 Jul 19.
7
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.来那度胺、硼替佐米与地塞米松联合移植治疗骨髓瘤
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
8
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.来那度胺的临床药代动力学与药效学
Clin Pharmacokinet. 2017 Feb;56(2):139-152. doi: 10.1007/s40262-016-0432-1.
9
Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).癌症临床试验中的患者报告结局：使用美国国立癌症研究所不良事件通用术语标准的患者报告结局版本（PRO-CTCAE）测量症状性不良事件。
Am Soc Clin Oncol Educ Book. 2016;35:67-73. doi: 10.1200/EDBK_159514.
10
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.来那度胺诱发的骨髓瘤患者腹泻是由胆汁酸吸收不良引起的，这种情况对治疗有反应。
Blood. 2014 Oct 9;124(15):2467-8. doi: 10.1182/blood-2014-06-583302.